Abstract library

340 results for "Gulati".
#1578 Everolimus Cumulative Dose and Dose Intensity in Pancreatic Neuroendocrine Tumors
Introduction: Everolimus represents a new treatment option for advanced pancreatic neuroendocrine tumors (pNETs).
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Prof. Rossana Berardi
#2076 Pancreatic Neuroendocrine Tumor in Polish Population with MEN 1 Syndrome
Introduction: The multiple endocrine neoplasia type 1 (MEN 1) is a genetically conditioned syndrome which is characterised by usually mild parathyroid and pituary gland adenomas, pancreatic neuroendocrine tumor (pNET). The last appear in 30-70% of MEN 1 patients being main life-threatening manifstation among MEN 1 patients. The prognosis might improve by presymptomatic tumor detection.
Conference: 15th Annual ENETS conference (2018)
Category: Endocrine malignancies (MTC, pheochromocytoma) - diagnosis and therapy
Presenting Author: MD Przemysław Soczomski
#840 Clinical Impact of Everolimus Cumulative Dose on Pancreatic Neuroendocrine Tumors (pNETs) Outcome
Introduction: Everolimus is approved for advanced pancreatic neuroendocrine tumors (pNETs).
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Rossana Berardi
#2905 DNA Methyltransferase Inhibitor Hydralazine Induces Upregulation of Somatostatin Type 2 Receptors in Human Neuroendocrine Tumor Cells
Introduction: Epidrugs like DNA methyltransferase inhibitors (DNMTi) can increase somatostatin receptor type 2 (SST2) expression in neuroendocrine tumor (NET) cells in vitro and in vivo. This effect could be used for NET patients with low SST2 expression who are currently ineligible for somatostatin analogue (SSA) treatment. However, the DNMTi known to stimulate SST2 have either a high toxicity profile or are not yet approved.
Conference: 17th Annual ENETS Conference (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Julie Refardt
#218 Survival Analyses of Pancreatic Neuroendocrine Tumors: Contrasting Institutional Databases with Population-Based Registries
Introduction: Prognostic data in pancreatic NETs derives from population-based studies, as well as from institutional databases.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jonathan Strosberg
Authors: Strosberg J, Halfdanarson T, ...
#976 Upregulation of Somatostatin Receptor Type 2 Expression in Neuroendocrine Tumors by Epigenetic Modulation
Introduction: The somatostatin receptor type 2 (sst2) is a target for treatment of neuroendocrine tumors (NETs). However, epigenetic mechanisms might account for the high variability in sst2 expression and treatment response between patients.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: MSc Marije J Veenstra
Keywords: GEP-NET, sst2, epigenetics
#200 Genome-Wide MicroRNA Expression in Small Intestine Neuroendocrine Tumors (“Midgut carcinoids”): Upregulation of miRNA-182, miRNA-183 and Downregulation of miRNA-215
Introduction: MicroRNAs (miRs) may regulate cell proliferation, differentiation, apoptosis and function as tumor suppressors or oncogenes. MiR expression is not characterized in neuroendocrine midgut carcinoids.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: PhD student Su-Chen Li
#462 Genome-Wide Expression Profiling Reveals Downregulation of OTP and CD44 and Upregulation of RET as Indicators of Poor Prognosis in Lung Carcinoids
Introduction: Lung carcinoids comprise a heterogeneous group of neuroendocrine tumors. Only few parameters have been identified that correlated with poor disease outcome, including 11q22-q25 deletions. New biomarkers are required to further improve diagnosis and prediction of prognosis.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: MSc Dorian Swarts
#2074 The Risk of Secondary Primary Colorectal Adenocarcinomas Is Not Increased among Patients with Gastroenteropancreatic Neuroendocrine Tumors – A Nationwide Population Based Study
Introduction: It has been suggested that secondary primary colorectal adenocarcinomas (SPCA) occur more often than normal in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Student Tobias Stemann Lau
#185 Czech Neuroendocrine Registry - First Results
Introduction: The Czech Neuroendocrine Registry was started in October 2009 as a platform that should facilitate the data based on communication among various specialists treating NETs.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Jaroslava Barkmanova
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team